Galapagos & Gilead Sciences to Begin New Phase 2 Study

Galapagos NV said late Tuesday that its collaboration partner Gilead Sciences will lead a new phase 2 proof-of-concept study evaluating filgotinib and another investigational agent in cutaneous lupus erythematosus, a form of lupus in the skin.

Walid Abi-Saab, chief medical officer of Galapagos said, “This is the first time we evaluate filgotinib in an autoimmune skin disorder,” adding that the company looks forward “to seeing whether filgotinib can impact signs and symptoms of CLE.” GLPG ADRs were up 0.3% while GILD shares were trading 2% higher recently.

Leave A Reply

Your email address will not be published.